Contributors to elevated baseline biomarker levels
| Variable . | cGFAP . | cNfL . | sNfL . | |||
|---|---|---|---|---|---|---|
| β 95% CI . | P value . | β 95% CI . | P value . | β 95% CI . | P value . | |
| Cohort 1 | ||||||
| Cohort 2 | −1.0 to −0.47 | <.001∗ | −0.06 to 0.48 | .13 | −0.62 to 0.09 | .14 |
| Cohort 3 | −0.93 to −0.27 | <.001∗ | −0.63 to 0.09 | .14 | −1.0 to −0.03 | .039 |
| Age at CAR T-cell infusion | −0.02 to 0.02 | >.9 | 0.00 to 0.04 | .053 | −0.02 to 0.03 | .6 |
| Sex | −0.39 to 0.10 | .2 | −0.37 to 0.12 | .3 | −0.31 to 0.34 | >.9 |
| Number of relapses | −0.07 to 0.17 | .4 | −0.05 to 0.19 | .3 | 0.08 to 0.40 | .003∗ |
| Number of HSCTs | 0.06 to 0.47 | .011 | −0.14 to 0.28 | .5 | −0.04 to 0.51 | .093 |
| No radiation | ||||||
| TBI | 0.00 to 0.56 | .048 | −0.09 to 0.44 | .2 | 0.11 to 0.82 | .010 |
| TBI + cranial boost | −0.13 to 0.57 | .2 | 0.36 to 1.0 | <.001∗ | −0.18 to 0.71 | .2 |
| CNS 1 | ||||||
| CNS 2 | −0.19 to 0.42 | .5 | −0.26 to 0.36 | .5 | −0.10 to 0.72 | .14 |
| CNS 3 | −0.22 to 1.4 | .2 | −0.19 to 1.5 | .13 | −0.73 to 1.5 | .5 |
| Neuro comorbidities | −0.12 to 0.38 | .3 | 0.07 to 0.56 | .012∗ | −0.26 to 0.39 | .7 |
| Peripheral neuropathy | −0.23 to 0.44 | .5 | −0.10 to 0.57 | .2 | 0.08 to 0.92 | .020∗ |
| Variable . | cGFAP . | cNfL . | sNfL . | |||
|---|---|---|---|---|---|---|
| β 95% CI . | P value . | β 95% CI . | P value . | β 95% CI . | P value . | |
| Cohort 1 | ||||||
| Cohort 2 | −1.0 to −0.47 | <.001∗ | −0.06 to 0.48 | .13 | −0.62 to 0.09 | .14 |
| Cohort 3 | −0.93 to −0.27 | <.001∗ | −0.63 to 0.09 | .14 | −1.0 to −0.03 | .039 |
| Age at CAR T-cell infusion | −0.02 to 0.02 | >.9 | 0.00 to 0.04 | .053 | −0.02 to 0.03 | .6 |
| Sex | −0.39 to 0.10 | .2 | −0.37 to 0.12 | .3 | −0.31 to 0.34 | >.9 |
| Number of relapses | −0.07 to 0.17 | .4 | −0.05 to 0.19 | .3 | 0.08 to 0.40 | .003∗ |
| Number of HSCTs | 0.06 to 0.47 | .011 | −0.14 to 0.28 | .5 | −0.04 to 0.51 | .093 |
| No radiation | ||||||
| TBI | 0.00 to 0.56 | .048 | −0.09 to 0.44 | .2 | 0.11 to 0.82 | .010 |
| TBI + cranial boost | −0.13 to 0.57 | .2 | 0.36 to 1.0 | <.001∗ | −0.18 to 0.71 | .2 |
| CNS 1 | ||||||
| CNS 2 | −0.19 to 0.42 | .5 | −0.26 to 0.36 | .5 | −0.10 to 0.72 | .14 |
| CNS 3 | −0.22 to 1.4 | .2 | −0.19 to 1.5 | .13 | −0.73 to 1.5 | .5 |
| Neuro comorbidities | −0.12 to 0.38 | .3 | 0.07 to 0.56 | .012∗ | −0.26 to 0.39 | .7 |
| Peripheral neuropathy | −0.23 to 0.44 | .5 | −0.10 to 0.57 | .2 | 0.08 to 0.92 | .020∗ |
Univariate linear regression was performed on log10-transformed measurements. P values < .05 are in bold. β 95% CI of the regression slope.
CI, confidence interval.
Variable selected in stepwise multivariate regression model, P < .05.